People with lupus often need to use medicines to manage their symptoms. Although there are many oral medicines that treat lupus, some people with more severe symptoms may not get enough benefit from ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

The U.S. Food and Drug Administration has approved GlaxoSmithKline's 200-mg subcutaneous route of administration of Benlysta (belimumab) for patients 5 years of age and older with active systemic ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a 200 mg Benlysta autoinjector for children aged 5 years and ...

The FDA approved a 200 mg/mL belimumab autoinjector for pediatric lupus nephritis, enabling at-home administration and reducing clinic visits. Lupus nephritis affects 30-50% of children with SLE, ...

Benlysta (belimumab) is a prescription drug that treats lupus by reducing the number of certain proteins in your blood that attack your body. Your response to this drug may vary based on your medical ...

MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...

The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...